edoxaban (savaysa) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Edoxaban (DU-176b, trade names Savaysa, Lixiana) is a selective factor Xa inhibitor reduces thrombin generation and thrombus formation and is an orally bioavailable anticoagulant drug. It was developed by Daiichi Sankyo to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis and pulmonary embolism following 5-10 days of initial therapy with a parenteral anticoagulant.   NCATS

Chemistry

  • SMILES: CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
  • InChIKey: HGVDHZBSSITLCT-JLJPHGGASA-N
  • Mol. Mass: 548.07
  • ALogP: 1.29
  • ChEMBL Molecules:
    edoxaban  
    edoxaban tosylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$8.2206 - $92.0920
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

du-176 | du176b | du-176b | edoxaban | edoxaban tosilate | edoxaban tosilate hydrate | edoxaban tosylate | edoxaban tosylate monohydrate | ethanediamide, n1-(5-chloro-2-pyridinyl)-n2-((1s,2r,4s)-4- ((dimethylamino)carbonyl)- 2-(((4,5,6,7-tetrahydro-5-methylthiazolo(5,4-c)pyridin-2-yl)carbonyl)amino)cyclohexyl)- | lixiana | n-(5-chloropyridin-2-yl)-n'-((1s,2r,4s)-4-(n,n-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide | n-(5-chloropyridin-2-yl)-n'-((1s,2r,4s)-4-(n,n-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)ethanediamide p-toluenesulfonate monohydrate | savaysa

Organizations (105)

Research & Development (104)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (53)

Approved Indications (5)


 

Atrial Fibrillation

Embolism

Pulmonary Embolism

Stroke

Venous Thrombosis

Experimental Indications - Clinical Trial Phases 1-4 (53)


 

Angina, Stable (Phase 4)

Anticoagulants (Phase 4)

Aortic Valve Stenosis (Phase 4)

Appendix (Phase 4)

Arthroplasty, Replacement, Hip (Phase 2)

Arthroplasty, Replacement, Knee (Phase 2)

Atrial Fibrillation ()

Atrial Flutter (Phase 4)

Atrial Function, Left (Phase 3)

Blood Coagulation (Phase 2)

Blood Coagulation Disorders (Phase 4)

Catheters (Phase 3)

Cerebral Hemorrhage (Phase 3)

Cerebral Infarction (Phase 2/Phase 3)

Cerebral Intraventricular Hemorrhage (Phase 3)

Cerebrovascular Disorders (Phase 3)

Coronary Artery Disease (Phase 4)

COVID-19 (Phase 3)

Diabetes Mellitus (Phase 4)

Drugs, Investigational (Phase 3)

Electric Countershock (Phase 3)

Embolism (Phase 3)

Embolism and Thrombosis (Phase 2)

Healthy Volunteers (Phase 2)

Heart Diseases (Phase 3)

Hematoma, Subdural (Phase 3)

Hemorrhage (Phase 4)

Hip Injuries (Phase 2)

HIV Infections (Phase 2)

Hypertension, Pulmonary (Phase 3)

Inflammation (Phase 2)

Intracranial Hemorrhage, Hypertensive (Phase 3)

Intracranial Hemorrhages (Phase 4)

Ischemia (Phase 2/Phase 3)

Ischemic Attack, Transient (Phase 4)

Ischemic Stroke (Phase 4)

Liver Cirrhosis (Phase 2)

Mitral Valve (Phase 3)

Mitral Valve Stenosis (Phase 2)

Mouth Neoplasms (Phase 2/Phase 3)

Myocardial Infarction (Phase 2/Phase 3)

Myocardial Ischemia (Phase 4)

Neoplasms (Phase 4)

Peripheral Arterial Disease (Phase 2)

Pulmonary Embolism (Phase 4)

Severe Acute Respiratory Syndrome (Phase 3)

Stroke (Phase 4)

Subarachnoid Hemorrhage (Phase 3)

Thromboembolism (Phase 4)

Thrombosis (Phase 4)

Upper Extremity Deep Vein Thrombosis (Phase 4)

Venous Thromboembolism (Phase 4)

Venous Thrombosis ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 86
  • # of Trial Organizations: 104

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue